Differences in levels of heart fat in people living with HIV and the general population

The association of ectopic fat and cardiovascular disease in people living with HIV and general populations: a cross-sectional analysis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN47550369

Enrollment

100

Registered

2024-02-16

Start date

2024-03-01

Completion date

Unknown

Last updated

2024-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epicardial adipose tissue (EAT) volume and cardiovascular (CVD) risk in people living with HIV and general populations Circulatory System

Interventions

Pre-screening. Participants will be approached for their interest to be involved in the study from routine clinics. If they are interested then a copy of the patient information leaflet will be provid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. >40 years old 2. HIV-positive 3. Stable ART for >6 months with two VL 200cells/mm3 for >2 years from recruitment 5. Understand the study procedures, be able to comply with study procedures and voluntarily agree to participate by giving informed written consent

Exclusion criteria

Exclusion criteria: 1. Subjects unable to comply with the study protocol 2. History of severe renal impairment (eGFR 9) 4. Active hepatitis B or hepatitis C 5. Any active illness, which in the opinion of the investigator precludes participation in the study 6. History of cancer 7. Active illicit intravenous drug use 8. Investigators may decide the subject cannot proceed if there are any relevant other abnormal results in screening assessments 9. History or current GLP-1 agonist use 10. For female subjects: pregnancy or breastfeeding at screening. 11. Subjects currently taking: Atypical antipsychotics, omega 3 supplements, Telmisartan/Irbesartan, Thiazolidinediones or regular NSAID use 12. Familial hypercholesterolaemia

Design outcomes

Primary

Measure	Time frame
Epicardial adipose tissue (mls) measured using cardiac MRI at MRI study visit	—

Secondary

Measure	Time frame
1. Intramyocardial triglyceride concentration (ppm) measured using MR spectroscopy at the MRI study visit 2. Fatty liver (KPa) measured using Fibroscan at screening visit (visit 1) 3. LV ejection fraction (%) measured using cardiac MIR at MRI study visit 4. T1 mapping (ms) measured at cardiac MRI at MRI study visit 5. T2 mapping (ms) measured at cardiac MRI at MRI study visit 6. Left atrial size (mls) measured at cardiac MRI at MRI study visit 7. LV mass (grams) measured at cardiac MRI at MRI study visit 8. Lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride (mmol/L)) measured at screening visit (visit 1) 9. HBA1c (mmol/mol) measured at screening visit (visit 1) 10. Adiponectin (ug/ml) measured at screening visit (visit 1) 11. Glucose (mmol/L) measured at screening visit (visit 1) 12. Insulin (IU/ml) measured at screening visit (visit 1) 13. HS-CRP (mg/dl) measured at screening visit (visit 1) 14. Leptin (ng/ml) measured at screening visit (visit 1) 15. Follow up 5 year data measured at 5 year telephone follow up	—

Measure

Time frame

1. Intramyocardial triglyceride concentration (ppm) measured using MR spectroscopy at the MRI study visit 2. Fatty liver (KPa) measured using Fibroscan at screening visit (visit 1) 3. LV ejection fraction (%) measured using cardiac MIR at MRI study visit 4. T1 mapping (ms) measured at cardiac MRI at MRI study visit 5. T2 mapping (ms) measured at cardiac MRI at MRI study visit 6. Left atrial size (mls) measured at cardiac MRI at MRI study visit 7. LV mass (grams) measured at cardiac MRI at MRI study visit 8. Lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride (mmol/L)) measured at screening visit (visit 1) 9. HBA1c (mmol/mol) measured at screening visit (visit 1) 10. Adiponectin (ug/ml) measured at screening visit (visit 1) 11. Glucose (mmol/L) measured at screening visit (visit 1) 12. Insulin (IU/ml) measured at screening visit (visit 1) 13. HS-CRP (mg/dl) measured at screening visit (visit 1) 14. Leptin (ng/ml) measured at screening visit (visit 1) 15. Follow up 5 year data measured at 5 year telephone follow up

—

Countries

England, United Kingdom

Contacts

Public ContactKaren Jennings-Wilding

hezmondo@liverpool.ac.uk+44 (0)1517951780

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026